SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

London, G.M., Guérin, A.P., Verbeke, F.H., Pannier, B., Boutouyrie, P., Marchias, S.J. and Mëtivier, F. (2007) Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency. Journal of the American Society of Nephrology, 18, 613-620.
http://dx.doi.org/10.1681/ASN.2006060573

has been cited by the following article:

  • TITLE: Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients

    AUTHORS: Kazumichi Matsushita, Keitaro Sato, Kohei Unagami, Kosaku Nitta, Kiichiro Tago

    KEYWORDS: Hemodialysis, Calcitriol, Sevelamer Hydrochrolide, Lanthanum Carbonate, Bioavailability

    JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.20, November 25, 2014

    ABSTRACT: Back ground: There are no published clinical data in hemodialysis (HD) patients with mineral bone disorder (CKD-MBD) regarding the effect of sevelamer hydrochloride on the absorption of the oral calcitriol. Objectives: The aim of the present study was to determine the association of the sevelamer hydrochloride and serum 1-25(OH)2D concentration during oral calcitriol therapy. Methods: This was a before-and-after study in HD patients. Forty-six patients co-administered with phosphate-binder and calcitriol for CKD-MBD therapy took lanthanum carbonate (LC) and sevelamer hydrochloride (SH) for 4 weeks, respectively with calcitriol. The serum 1-25(OH)2D concentration was assessed after each period. Results: Serum 1-25(OH)2D concentration was significantly reduced with co-administration of SH compared to LH (mean, calcitriol with LC→SH: 19.9 pg/ml → 14.2 pg/ml, p 2D concentrations after oral calcitriol administration compared to LH in HD patients. When we use SH as a phosphate binder with calcitriol for HD patients with CKD-MBD, we should consider the inhibitory effect of SH on oral calcitriol absorption.